A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01220271 |
|
Recruitment Status :
Completed
First Posted : October 13, 2010
Last Update Posted : February 16, 2017
|
Sponsor:
Eli Lilly and Company
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this trial is to show proof of concept that by blocking the Transforming Growth Factor-beta signaling pathway in patients with Glioblastoma, there will be clinical benefit.
Phase 1b: To determine the safe and tolerable dose of LY2157299 in combination with radiochemotherapy with temozolomide for Phase 2 in patients with glioma eligible to receive radiochemotherapy with temozolomide (e.g. newly diagnosed malignant glioma World Health Organization Grade III and IV).
Phase 2a: To confirm the tolerability and evaluate the pharmacodynamic effect of LY2157299 in combination with standard radiochemotherapy in patients with newly diagnosed glioblastoma.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Glioma | Drug: LY2157299 Drug: Radiation Drug: Temozolomide | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 75 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma |
| Study Start Date : | April 2011 |
| Actual Primary Completion Date : | August 2015 |
| Actual Study Completion Date : | November 2016 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Temozolomide
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 1: 160 mg LY2157299
During Radiation therapy:
After Radiation Therapy:
|
Drug: LY2157299
Administered orally Drug: Radiation Administered as approved Drug: Temozolomide Administered orally |
|
Experimental: Phase 1: 300 mg LY2157299
During Radiation therapy:
After Radiation Therapy:
|
Drug: LY2157299
Administered orally Drug: Radiation Administered as approved Drug: Temozolomide Administered orally |
|
Experimental: Phase 2: Established dose LY2157299
During Radiation therapy:
After Radiation Therapy:
|
Drug: LY2157299
Administered orally Drug: Radiation Administered as approved Drug: Temozolomide Administered orally |
|
Experimental: Phase 2: no LY2157299 (control)
During Radiation therapy:
After Radiation Therapy: Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles. |
Drug: Radiation
Administered as approved Drug: Temozolomide Administered orally |
Primary Outcome Measures :
- Phase 1: Recommended dose for Phase 2 portion [ Time Frame: Baseline to phase 1 completion ]
- Phase 2: Relationship of change in response biomarker to clinical benefit [ Time Frame: Baseline through discontinuation from any cause ]
Secondary Outcome Measures :
- Phase 1: Pharmacokinetics - Concentration Maximum [ Time Frame: Baseline, prior to first dose of cycle 1 and 2 and on days 1, 3, 8, 14, 15 and 16 ]
- Phase 1: Number of patients with a tumor response [ Time Frame: Baseline to Progressive Disease ]
- Phase 2: Overall Survival at 12 Months [ Time Frame: Randomization to date of death from any cause at 12 months ]
- Phase 2: Overall Survival [ Time Frame: Randomization to date of death from any cause ]
- Phase 2: Progression Free Survival [ Time Frame: Randomization to measured progressive disease or death from any cause ]
- Phase 2: Proportion of patients achieving an objective response (Response Rate) [ Time Frame: Randomization to measured progressive disease ]
- Phase 2: Duration of tumor Response [ Time Frame: Time of response to measured progressive disease or death from any cause ]
- Phase 2: Time to Treatment Failure [ Time Frame: Randomization to the date of discontinuation of study treatment due to adverse event, progression of disease, or death from any cause ]
- Phase 1: Pharmacokinetics - Time to Concentration Maximum [ Time Frame: Baseline, prior to first dose of cycle 1 and 2 and on days 1, 3, 8, 14, 15 and 16 ]
- Phase 1: Pharmacokinetics - Area under the Curve [ Time Frame: Days 12 to 14 in cycle 1 and in cycle 3 ]
- Phase 2: Change from baseline in MD Anderson Symptom Inventory - Brain Tumor [ Time Frame: Baseline, 30 day post study day follow-up ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with histologically proven, newly diagnosed and untreated intracranial glioblastoma including lower grade glioma which evolved into glioblastoma and who have not received any radiochemotherapy or who have World Health Organization Grade III malignant glioma (e.g., Anaplastic Astrocytomas, Anaplastic Oligoastrocytomas, Anaplastic Oligodendroglioma) (Phase 1b only) will be eligible for this protocol
- Biopsy or resection must have been performed no more than 6 weeks prior to treatment
- An Magnetic Resonance Imaging must be obtained within 72 hours after surgery, preferably within 48 hours
- Patient must not have had prior cranial radiation therapy
- Patients must not have received prior cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors Patients who received Gliadel wafers at the time of original resection will be excluded
- Patients must plan to begin partial brain radiotherapy within 2-6 weeks after surgery. Regular fractionated radiotherapy with photons (in any planning mode and possibly image-guided or stereotactic if deemed necessary) is performed according to the discretion of the investigator
- Patients must be willing to forego other cytotoxic and noncytotoxic drug therapy against the tumor while being treated with LY2157299 and temozolomide
- All patients must sign an informed consent indicating that they are aware of the investigational nature of this study
- Patients must have performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- Patients must have adequate hematologic, hepatic and renal function
- Male and female patients with reproductive potential must use an approved contraceptive method,during and for 6 months after discontinuation of study treatment Women of childbearing potential must have a negative human chorionic gonadotropin pregnancy test documented within 14 days prior to treatment
Exclusion Criteria:
- Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or not approved use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
-
Have moderate or severe cardiac disease as defined by any of the following:
- Have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension
- Have documented major electrocardiogram (ECG) abnormalities that are symptomatic and are not medically controlled
- Have major abnormalities documented by echocardiography with Doppler
- Have predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress
- Are unable to swallow tablets or capsules
- Are pregnant or breastfeeding
- Have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
- Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and stopped all therapy for that disease for a minimum of 3 years are ineligible
- Have active infection that would interfere with the study objectives or influence the study compliance
- Stereotactic radiosurgery, such as Gamma-Knife treatment, and brachytherapy are not allowed in this study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01220271
Locations
| United States, California | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| La Jolla, California, United States, 92093 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| San Francisco, California, United States, 94143 | |
| United States, Florida | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Tampa, Florida, United States, 33612 | |
| United States, Illinois | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Chicago, Illinois, United States, 60611 | |
| United States, Indiana | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, North Carolina | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Durham, North Carolina, United States, 27710 | |
| Germany | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Frankfurt, Germany, 60596 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Heidelberg, Germany, 69120 | |
| Spain | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Barcelona, Spain, 08035 | |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
| Madrid, Spain, 28041 | |
Sponsors and Collaborators
Eli Lilly and Company
Investigators
| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT01220271 |
| Other Study ID Numbers: |
11585 H9H-MC-JBAI ( Other Identifier: Eli Lilly and Company ) |
| First Posted: | October 13, 2010 Key Record Dates |
| Last Update Posted: | February 16, 2017 |
| Last Verified: | February 2017 |
Keywords provided by Eli Lilly and Company:
|
Glioma Glioblastoma |
Additional relevant MeSH terms:
|
Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial |
Neoplasms, Nerve Tissue Temozolomide Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |